YHLO contributes to SARS-CoV-2-specific immune response research in COVID-19 convalescent individuals
Recently, Zhongnan Hospital of Wuhan University used YHLO reagents to further analyze the protective immunity of SARS-CoV-2, which provided a basis for understanding the pathogenesis of COVID-19 and provided assistance for the development of effective SARS-CoV-2 vaccine. The research has now been published in the journal Signal Transduction and Targeted Therapy (Impact Factor: 18.187)
A total of 212 samples from 171 COVID-19 convalescent individuals, with a median age of 52 years were enrolled in the study, and 212 blood samples were collected in three time periods (4-6 months, 7-8 months and 9-11 months after diagnosis). At the same time, 30 healthy volunteers were recruited to collect blood samples.
Using serum from patients and healthy donors, IgA, IgM and IgG antibodies against SARS-CoV-2 NP, S1, RBD and NP-S1 antigens were detected. Compared with healthy donors, in follow-up patients, anti-SARS-CoV-2 IgG antibodies are also pronounced than IgA and IgM antibodies until at least 11 months after onset.
Among the patients who were followed up for 4-6 months after the onset, 67.3% (37/55) of the patients were NAb-positive, while 94.4% (67/71) and 71.4% (60/84) of patients had positive NAb within 7–8 months and 9–11 months after the diagnosis, respectively. As expected, NAb was significantly associated with anti-S1 IgG and anti-RBD IgG, but not with anti-NP IgG, indicating that anti-S1 IgG and anti-RBD IgG may be predictors of serum neutralization ability in COVID-19 patients. These findings indicate that most individuals in the recovery phase of COVID-19 have serum that neutralizes SARS-CoV-2 for at least 11 months after the onset of disease.
This study used chemiluminescence SARS-CoV-2 NAb kits produced by Shenzhen YHLO Biotech Co., Ltd were used for the evaluation of NAbs in patients recovering from COVID-19 or the auxiliary evaluation of the effect of the SARS-CoV-2 vaccine. The iFlash-SARS-CoV-2 IgA/IgG/IgM assay was used for qualitative determination of the IgG antibody to SARS-CoV-2 in human serum or plasma using the iFlash immunoassay system. The iFlash-SARS-CoV-2 IgA/IgG/IgM aids in the diagnosis of SARS-CoV-2 infection and the determination of immunity.
Original publication:
Pan Y, Jiang X, Yang L, et al. SARS-CoV-2-specific immune response in COVID-19 convalescent individuals[J]. Signal Transduction and Targeted Therapy, 2021, 6(1): 1-10.
#Vaccines #Diagnostics #Serology #COVID19 #SARSCoV2 #Coronavirus #BindingAntibodies #NeutralizingAntibodies #NAbs #Covid19testing #Covid19solutions
Attachments:
MORE NEWS
n November 18, 2025, YHLO’s 2025 Global Core Distributors Conference was successfully held in Düsseldorf, Germany. Under the theme “Academia-Driven, Shared Value,” the meeting brought together representatives from more than 30 core distributors worldwide. YHLO’s founder, Mr. Deming Hu, and Chairman, Mr. Kunhui Hu, led the company’s executive team to attend and discuss strategic development with partners.
2025-11-20
YHLO Secures Approval for the World’s First sCD146 CLIA Assay
YHLO has obtained approval from the Guangdong Medical Products Administration for its soluble CD146 (sCD146) CLIA assay, marking a major milestone in central nervous system (CNS) disease diagnostics. YHLO is now the first company worldwide to offer an sCD146 test for cerebrospinal fluid, bringing its total CLIA assay portfolio in China to 173.
2025-11-18
Add: Building 1, YHLO Biopark, Baolong 2nd Road, Baolong Subdistrict, Longgang District, 518116 Shenzhen, P.R.China
